Thomsen Jillian B. 4
4 · NEKTAR THERAPEUTICS · Filed Jan 29, 2021
Insider Transaction Report
Form 4
Thomsen Jillian B.
VP & Chief Accounting Officer
Transactions
- Exercise/Conversion
Common Stock
2021-01-28$8.80/sh+37,500$330,000→ 251,257 total - Exercise/Conversion
Stock Option
2021-01-28−37,500→ 0 totalExercise: $8.80From: 2017-02-06Exp: 2021-02-05→ Common Stock (37,500 underlying) - Exercise/Conversion
Stock Option
2021-01-28−37,500→ 0 totalExercise: $8.80From: 2017-02-06Exp: 2021-02-05→ Common Stock (37,500 underlying) - Sale
Common Stock
2021-01-28$18.62/sh−75,000$1,396,500→ 176,257 total - Exercise/Conversion
Common Stock
2021-01-28$8.80/sh+37,500$330,000→ 213,757 total
Footnotes (3)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021.
- [F2]This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
- [F3]This transaction was executed in multiple trades at prices ranging from $18.26 to $19.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.